Table 1

Baseline characteristics

Number of patients51
Age, years (SD*)59 (11.2)
Female, No (%)29 (57)
Weight, kg (SD)75 (13)
Disease duration in years, median (p25–p75)12 (9–18)
RF positive, No (%)42 (82)
Anti-CCP positive, No (%)37 (73)
Erosive disease, No (%)39 (76)
DAS28 at inclusion (SD)2.5 (0.7)
Duration of infliximab therapy, years (SD)5.6 (2.6)
Interval duration at start, median (p25–p75)8 (6–8)
Infliximab dose at start, mg (SD)223 (41)
Infliximab at start, mg/kg (SD)3.0 (0.2)
No of previous DMARDs, median (p25–p75)3 (2–3)
Previous MTX, No (%)49 (96)
Previous anti-TNF-α therapy, No (%)5 (10)
Concomitant DMARD use, No (%)41 (80)
Concomitant MTX use, No (%)35 (68)
Concomitant corticosteroid use, No (%)2 (4)
Concomitant NSAID use, No (%)27 (53)
Employment, No (%)16 (31)
  • Anti-CCP, anti-cyclic citrullinated peptide; DAS28, 28-joint disease activity score; DMARD, disease modifying antirheumatic drugs; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor; TNF, tumour necrosis factor.